Modality
ADC
MOA
CD3xCD20
Target
USP1
Pathway
Lipid Met
Celiac
Development Pipeline
Preclinical
~Mar 2022
→ ~Jun 2023
Phase 1
~Sep 2023
→ ~Dec 2024
Phase 2
Mar 2025
→ Aug 2028
Phase 2Current
NCT03668467
988 pts·Celiac
2025-03→2028-08·Terminated
988 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-192.4y awayPh2 Data· Celiac
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Termina…
Catalysts
Ph2 Data
2028-08-19 · 2.4y away
Celiac
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03668467 | Phase 2 | Celiac | Terminated | 988 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | GPRC5D | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |